Revisable Quick List of New Drugs for PG Entrance Exams

Date: Sunday, November 20 @ 01:10:41 IST

Topic: Pharmacology

Print this page

Having a handy and brief list of all the latest drugs in the market can
be very useful for the medical PG entrance exams. Exams conducted
by AIIMS are particularly prone to have one or two such questions as
they asked about Bosentan in 2002 and Pyronaridine in 2003
(luckily there were none in the recent AIIMS exam). For an example
see this thread from 2003 wherein RxPG members got one such answer
right because they discussed it in forums beforehand. As 90% of exam
takers will either leave or mark such questions incorrectly, getting
such questions right can give you an advantage. In view of the
upcoming AIPGE exam, we asked one of our team members to scour
the web and make an extremely brief (=revisable) list of new drugs
launched in last three years. We decided to include only the relevant
"NEW" drugs (not the variants of older drugs) and kept the description
limited to only one line for each of the drugs. This article from us
covers all newly marketed drugs which might not be there in your
textbooks yet!

--------------------------------
2005
--------------------------------
Exenatide: For the adjunctive treatment of Type 2 diabetes mellitus
Mecasermin: For the treatment of growth failure due to Primary IGFD
Pramlintide: For the treatment of type I and type II diabetes
Tipranavir: For the adjunctive treatment of HIV-1 infections
Entecavir: For the treatment of chronic hepatitis B infections with
evidence of active viral replication
Ibandronate: For the treatment and prevention of osteoporosis
Galsulfase: For the treatment of mucopolysaccharidosis VI
(Maroteaux-Lamy syndrome)
Ramelteon: For the treatment of sleep-onset insomnia
Natalizumab: For the treatment of relapsing forms of multiple sclerosis
Nelarabine: For the treatment of T-cell acute lymphoblastic leukemia
and T-cell lymphoblastic lymphoma

--------------------------------
2004
--------------------------------
Bevacizumab: For the treatment of metastatic carcinoma of the colon
or rectum
Cetuximab: For the treatment of EGFR-expressing, metastatic
colorectal cancer
Azacitidine: For the treatment of several myelodysplastic syndrome
subtypes including refractory and chronic myelomonocytic leukemias
Telithromycin: For the treatment of infections caused by bronchitis,
bacterial sinusitis and Community-acquired pneumonia
Rifaximin: For the treatment of Travelers' diarrhea caused by
noninvasive strains of Escherichia coli
Fosrenol, lanthanum carbonate; For the treatment of
hyperphosphatemia related to kidney dysfunction
Trospium chloride: For the treatment of overactive bladder with
symptoms of urge urinary incontinence
Cinacalcet: For the treatment of secondary hyperparathyroidism and
hypercalcemia in parathyroid carcinoma patients
Solifenacin succinate: For the treatment of overactive bladder with
symptoms of urge urinary incontinence
Eszopiclone: For the treatment of insomnia and sleep maintenance
Natalizumab: For the treatment of relapsing forms of multiple sclerosis
(currently suspended in US)
clofarabine: For the treatment of acute lymphoblastic leukemia in
pediatric patients
Erlotinib, OSI 774: For the treatment of advanced refractory
metastatic non-small cell lung cancer
Pegaptanib: For the treatment of wet age-related macular
degeneration
Duloxetine: For the treatment of major depressive disorder
Tiotropium bromide: For the treatment of bronchospasm associated
with chronic obstructive pulmonary disease

--------------------------------
2003
--------------------------------
Rosuvastatin calcium: For the treatment of primary
hypercholesterolemia (heterozygous familial and nonfamilial) and
mixed dyslipidemia
Vardenafil: For the treatment of erectile dysfunction related to sexual
activity in men
Alefacept: For moderate to severe chronic plaque psoriasis
Laronidase: For the treatment of Mucopolysaccharidosis I (MPS I) in
subjects aged 5 to 65
Agalsidase beta: For the treatment of Fabry disease in adult patients
Pegvisomant: Injectable formulation for the treatment of acromegaly
Palonosetron: For the prevention of nausea and vomiting associated
with emetogenic cancer chemotherapy
Aprepitant: For the treatment of nausea and vomiting associated with
chemotherapy
Bexxar; For the treatment of patients with CD20 positive, follicular,
non-Hodgkin's lymphoma following chemotherapy relapse
Atazanavir sulfate: For the treatment of HIV-1 infection in combination
with other antiretroviral agents
Zemaira (alpha1-proteinase inhibitor: For the treatment of alpha1-
proteinase inhibitor deficiency (Alpha-1) and emphysema
Enfuvirtide: For the treatment of HIV-1 infection in combination with
other antiretroviral agents
Fosamprenavir calcium: For the treatment of HIV infection in adults in
combination with other antiretroviral agents
Atazanavir sulfate: For the treatment of HIV-1 infection in combination
with other antiretroviral agents
Laronidase: For the treatment of Mucopolysaccharidosis I (MPS I) in
subjects aged 5 to 65
Ibandronate: For the treatment and prevention of osteoporosis
Pegvisomant: Injectable formulation for the treatment of acromegaly
Bortezomib: Injectable agent for the treatment of multiple myeloma
patients who have received at least two prior therapies
Agalsidase beta: For the treatment of Fabry disease in adult patients
Tadalafil: Oral agent for the treatment for erectile dysfunction
Memantine: For the treatment of moderate to severe dementia of the
Alzheimer’s type
Palonosetron: For the prevention of nausea and vomiting associated
with emetogenic cancer chemotherapy
Aprepitant: For the treatment of nausea and vomiting associated with
chemotherapy
Gefitinib: For the second-line treatment of non-small-cell lung cancer
Bortezomib: Injectable agent for the treatment of multiple myeloma
patients who have received at least two prior therapies.
Gefitinib: For the second-line treatment of non-small-cell lung cancer

References: FDA Website (main source of background information).

We recieved some feedback from students that this list does not cover
Herceptin (new breast cancer drug). We should mention here that
Herceptin was approved in 1998 (not in last three years as covered by
the list above) and we have a dedicated article covering it at
http://www.rxpgonline.com/article1478.html